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Introduction: A systemic anticoagulation is often required to prevent circuit and filter clotting in ICU patients
undergoing continuous renal replacement therapy (CRRT). A regional citrate-based anticoagulation (RCA) does not
induce a systemic anticoagulation and prolongs the filter lifespan, but metabolic side-effects have been associated
with this therapy. We conducted a randomized controlled trial with patients requiring CRRT to determine whether
RCA using a balanced predilution replacement fluid is more effective than heparin in terms of renal replacement
delivered dose and safety profile.
Methods: One hundred and three patients with AKI requiring CRRT were included. The patients were randomized
to either CRRT with RCA or heparin anticoagulation. Primary endpoints were effective daily delivered RRT dose
during the first 3 days of CRRT and filter lifespan. Secondary endpoints were 28-day and 90-day survival and severe
metabolic complications and bleeding disorders.
Results: Median CRRT duration was 3.0 (2–6) days. Effective delivered daily RRT doses were 29 ± 3 and 27 ± 5 mL/kg/hr
in the RCA and heparin groups, respectively (p = 0.005). Filter lifespans were 49 ± 29 versus 28 ± 23 hrs in the RCA and
heparin groups (p = 0.004). Survival rates at 28 and 90 days were 80-74% in the RCA and 74-73% in the heparin group.
Electrolytes and acid–base disturbances were uncommon and transient in patients treated with RCA.
Conclusions: These results show that RCA is superior to heparin-based anticoagulation in terms of delivered RRT dose
and filter life span and is a safe and feasible method. This does not translate into an improvement in short term
survival.
Trial registration: ClinicalTrials.gov NCT01269112. Registered 3rd January 2011.Introduction
Acute kidney injury (AKI) is a common complication in
the ICU setting, occurring in nearly 5 to 7% of the
patients and burdened by a high mortality rate [1]. Renal
replacement therapy (RRT) is needed in 70% of ICU
patients with AKI and continuous renal replacement
therapy (CRRT) is implemented in 80% of the cases [1].* Correspondence: Patrick.Saudan@hcuge.ch
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unless otherwise stated.Systemic anticoagulation is often required to prevent
clotting of the filter and extracorporeal circulation. Until
recently unfractionated heparin was the standard and
the most-used anticoagulation therapy in the ICU setting
[2]. However, ICU patients are at higher risk of bleeding
for many reasons (surgical procedures, trauma, liver dys-
function, thrombocytopenia), and this risk is increased
when systemic anticoagulation is used.
By chelating calcium, citrate inhibits the clotting cas-
cade and thrombin generation, and can therefore be
used to specifically anticoagulate the extracorporeal cir-
culation and filter during CRRT. The use of postfilter. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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systemic calcium levels and full systemic coagulation
[3,4]. Citrate can induce severe hypocalcemia, as well as
other metabolic disorders such as metabolic alkalosis or
acidosis, especially acidosis in patients with severe liver
impairment as citrate is mainly metabolized into bicar-
bonate by the liver. To avoid these serious side-effects,
protocols of regional citrate administration have been
developed along with the use of postfilter and systemic
ionized calcium measurements. This enables modulation
of citrate flow rate within the extracorporeal circuit, as
well as calcium supplementation, in order to maintain
anticoagulation in the circuit and normal systemic cal-
cium levels.
Some human studies have demonstrated that regional
citrate-based anticoagulation (RCA) may extend the fil-
ter lifespan and therefore minimize filter clotting, circuit
downtime and blood losses [5-9]. A decrease in mortal-
ity has also been observed in the largest RCT published
to date, although this was not confirmed in a subsequent
trial [10,11].
According to the new Kidney disease improving global
outcomes (KDIGO) guidelines, RCA should be now the
first choice for CRRT anticoagulation [12]. Due to time-
consuming procedures and a more complex protocol, its
implementation within the ICU setting can however, be
more difficult than use of standard heparin. Citrate can
be administered prefilter, either as a separate solution, or
contained within a balanced predilution replacement
solution.
As this modality may be more caregiver-friendly in
terms of implementation, we conducted a randomized
controlled trial in ICU patients requiring CRRT to deter-
mine whether a balanced predilution replacement fluid
with citrate was more effective than heparin in terms of
delivered renal replacement dose, filter lifespan, safety
profile and patient survival.
Methods
Study design and outcomes
The study was a monocentric prospective open-label
randomized controlled trial at the ICU of the University
Hospitals of Geneva (Switzerland). The study was ap-
proved by the local ethical committee from the Geneva
University Hospitals and registered at ClinicalTrials.gov
(NCT01269112). A consent form was obtained from all
enrolled patients, their next-of-kin or a senior ICU phys-
ician who was neither in charge of the patient nor in-
volved in the study. Consent was sought and confirmed
whenever patients regained decision-making capacity.
Setting and patients
The Geneva University Hospitals ICU is a 36-bed unit
taking care of medical, surgical, trauma, and transplantpatients (n = 2,600 admissions/yr). CRRT indications and
implementations are under the supervision of intensive
care physicians and nephrologists with the involvement
of the nephrology nurses for the CRRT set up.
Inclusion criteria
ICU patients were eligible if they were ≥18 years of age
and had an AKI requiring CRRT according to the
kidney-failure criteria of the RIFLE definition [13].
Exclusion criteria
Patients were excluded if they had active hemorrhagic
disorders or severe thrombocytopenia (<50 × 109/L), a
history of heparin-induced thrombocytopenia, severe
liver failure defined as a factor V <20%, or were on the
waiting list for liver transplantation.
Treatment assignment
Subjects enrolled into the trial were randomly allocated to
either heparin or citrate anticoagulation. A randomization
list was generated by computer in random blocks of five
patients, and blinded for the investigators. Sealed, opaque
and sequentially numbered envelopes with the respective
allocation cards were prepared by the Unit of Quality
Care. The on-call nurse from the Nephrology Unit opened
the next available envelope each time a patient was en-
rolled in the study. Blinding was impossible to perform for
obvious logistic reasons. A unique identification code was
assigned to the subject at inclusion. Data were collected
and analyzed using this anonymous number.
Intervention
CRRT was performed in both arms by pump-driven de-
vices (Prismaflex-Gambro Lundia, Lund, Sweden) with fluid
balance systems and a biocompatible high-flux membrane
measuring 1.5 m2 (ST-150; Gambro). Continuous veno-venous
hemodiafiltration (CVVHDF) was started at a dose of
30 ml/kg/h, of which 10 ml/kg/h were dialysate flow.
Two thirds of the replacement fluids were administered
in the predilution mode and one third in the postdilu-
tion mode. Our dose protocol was tailored to match a
25 ml/kg/h dialysis dose obtained in the postdilution
mode in order to compensate for the lower efficacy of
our 2/3 predilution protocol. As our predilution reinjec-
tion flow rate adds 16% more fluid to our blood flow
rate, we estimated that 30 ml/kg/h would be equivalent
to the dialysis dose implemented in the renal trial [14].
The ultrafiltration rate was adapted by the ICU team ac-
cording to clinical criteria, with a recommendation not
to exceed 200 ml/kg/h. In the absence of clotting, the fil-
ter was changed after 72 h following manufacturer’s rec-
ommendations. A double-lumen catheter was inserted
through a central vein. A triple-lumen catheter was used
when no other central venous line was available for
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100 and 200 ml/min. All solutions except Prismocitrate
contained bicarbonate.
Citrate
CVVHDF was performed using Prismocitrate 18/0 so-
lution (Trisodium citrate 18 mmol/L, Na+ 136 mmol/L,
Cl− 86 mmol/L) in the predilution mode, Prismocal B22
(Mg2+ 0.75 mmol/L, Na+140 mmol/L,K+ 4 mmol/L,
Cl−120.5 mmol/L, lactate 3 mmol/L HCO3- 22 mmol/L)
in the dialysate mode, and Prismasol (Ca2+ 1.75 mmol/L,
Mg2+ 0.5 mmol/L, Na+ 140 mmol/L, Cl−113.5 mmol/L,
lactate 3 mmol/L HCO3- 32 mmol/L, K
+ 4 mmol/L, glu-
cose 6.1 mmol/L) in the postdilution mode. All the solu-
tions were made and delivered by Gambro. The protocol
was designed to adjust the citrate solution flow rate to the
patients’ blood flow rate to target a blood citrate concen-
tration of 3 mmol/L. Blood flow was therefore maintained
between 100 and 200 ml/min according to the patient’s
body weight in order to achieve this target. In the case of
early signs of clotting, citrate dose was further adapted to
aim for a postfilter ionized calcium of 0.25 to 0.3 mmol/L.
Postfilter ionized calcium was measured 15 minutes after
any change in blood, reinjection, dialysate, or calcium flow
rates.
A protocol was followed by the intensive care nurses
(ionized systemic calcium and bicarbonate were mea-
sured by arterial blood gases every 3 h during the first
24 h, then every 5 h) to adapt the dialysate flow to main-
tain the blood pH within normal range, and to adapt the
postfilter calcium administration to prevent systemic
hypocalcemia.
Heparin
CVVHDF was performed using unfractionated heparin
as anticoagulant and Prismasol as reinjection and di-
alysate fluids. The dose of heparin was prescribed by
the intensive care physician depending on the patient’s
medical condition. A minimal dose of 500 UI/h was re-
quired to assure circuit patency. The treatment was
continued until recovery of renal function, which was
defined as a urine output of ≥1 ml/kg/h or stable plasma
creatinine values 24 h after CRRT discontinuation, or the
start of intermittent hemodialysis or death. Treatment was
stopped in the case of any adverse event possibly related
to the type of anticoagulation. The event was signaled and
treatment resumed or switched to the other mode of
anticoagulation, according to the judgment of the ICU
physician in charge of the patients.
Study endpoints
We assessed the following parameters during RRT
days: filter lifespan (duration of use until non elective
circuit disconnection due to filter clotting or effectivetransmembranous pressure >300 mmHg); daily delivered
RRT dose (ml/kg/h), corresponding to the h/day when the
prescribed RRT dose was delivered (including filter down-
time), a daily 30 ml/kg/h RRT dose being a delivered RRT
dose during 24 h without downtime; daily effective deliv-
ered RRT dose (ml/kg/h) corresponding to the h/day
when prescribed RRT dose was delivered (excluding
elective filter downtime, such as treatment interrup-
tions for radiological or surgical procedures); bleeding
episodes requiring transfusions; episodes of heparin-
induced thrombocytopenia (HIT); and metabolic disorders
(defined as metabolic alkalosis with pH >7.55, metabolic
acidosis with pH <7.25, clinically relevant hypocalcemia
with ionized calcium <1 mmol/L, citrate accumulation de-
fined as a Ca tot/Ca ion ≥2.5).
We assessed the following parameters during follow-up:
vital status at 28 and 90 days (survival, hospitalization and
requirement of maintenance RRT); primary outcomes of
mean daily delivered RRT dose during the first 3 days of
CRRT (ml/kg/h) and filter lifespan; secondary outcomes
of patient survival at 28 and 90 days, length of ICU stay,
bleeding episodes, occurrence of HIT and severe metabolic
disorders. Survival status was assessed according to the
Hospital database linked with the Geneva State Registry
office.
Statistics
Statistics were performed using SPSS18 software package
(SPSS Inc., Chicago IL, USA). All categorical variables are
presented as number and percentage and all continuous
variables with a normal distribution as mean ± SD. When
not normally distributed, variables are expressed as me-
dian and IQR. Parametric and non-parametric tests were
used to compare baseline characteristics of study groups.
For the primary outcome (filter lifespan), survival analysis
was assessed with Kaplan-Meier curves and groups were
compared by log rank test. Analyses were conducted on
an intention-to-treat basis. A two-side P-value <0.05 was
considered significant.
Sample size
We hypothesized that the effective daily CRRT dose
would be 95 ± 10% of the prescribed dose with citrate-
based replacement fluid and 75 ± 20% with heparin. We
calculated a sample size of 49 patients per arm to obtain
80% power with a two-sided α level <0.05 and to detect
a 20% change in the prescribed dose effectively deliv-
ered (primary outcome). The trial was stopped after
randomization of 103 patients.
Results
From October 2011 to July 2013, we screened 246 pa-
tients with AKI requiring CRRT within the Medical and
Surgical ICU of the Geneva University Hospitals. We
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allocated treatment. Reasons for non enrollment for the
remaining 143 patients are mentioned in the study flow
chart (Figure 1).
Demographic and clinical characteristics at baseline in
both arms are shown in Table 1. Baseline characteristics
were well-matched across groups.
Primary outcome
Mean daily delivered RRT dose for patients during RRT
were 29 ± 3 ml/kg/h in the RCA group and 27 ± 5 ml/kg/h
in the heparin group (P = 0.005). In the 52 patients who
did not need to have RRT stopped for elective reasons
during the first 3 days of RRT, the mean daily delivered
RRT dose for was 29 ± 5 ml/kg/h in the RCA group and
25 ± 4 ml/kg/h in the heparin group (P = 0.007), and the














Figure 1 Flow chart of the trial.group compared to the heparin one (49 ± 29 versus
28 ± 23 h, vs = 0.004) (Figure 2).
Secondary outcomes
Safety issues
Four patients in the citrate group were switched to hep-
arin during the study: one on account of worsening liver
failure, one on account of a technical problem with cal-
cium infusion, and two for clinically relevant hypocalce-
mia (one with concomitant intractable severe metabolic
acidosis due to septic shock and one whose treatment
was changed by the team for no clear reasons). In the
six patients with RCA who had severe hypocalcemia,
mean total calcium was 1.78 (0.10) mmol/L, ionized
calcium was 0.94 (0.27) mmol/L and Ca tot/calcium
ion ratio was 2.17 (1.20). Citrate accumulation, identi-
fied as a Ca ratio (total calcium/ionized calcium >2.5),46)
Allocated to Heparin 
(N=49)






ere liver failure : 40
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Table 1 Baseline characteristics of the participants according to randomization
Variables Citrate Heparin P
(n = 54) (n = 49)
Age 60 (14) 65 (16) 0.07
Male gender 32 (59) 32 (64) 0.55
Weight, kg 82 16) 80 (18) 0.67
Diabetes 19 (36) 16 (33) 0.73
Chronic kidney disease 22 (42) 17 (35) 0.48
Coronary artery disease 9 (17) 13 (27) 0.24
Cerebrovascular disease 4 (8) 4 (8) 0.91
Cardiac heart failure 13 (25) 15 (30) 0.49
Chronic liver disease 6 (11) 6 (12) 0.89
Cancer 6 (11) 10 (20) 0.21
Diagnosis of renal failure
(medical/trauma/surgical) 44 (81)/3 (5)/7 (13) 35 (71)/1 (2)/13 (27) 0.17
Laboratory data
Serum creatinine, μmol/L 471 (319) 455 (296) 0.89
BUN, mmol/L 27 (17) 26 (19) 0.80
Hemoglobin, g/L 104 (22) 107 (22) 0.52
Platelets, 109/L 217 (160) 181 (115) 0.20
INR 1.2 (0.3) 1.3 (0.4) 0.70
PTT, sec 46 (23) 53 (39) 0.24
pH 7.27 (0.16) 7.28 (0.14) 0.61
Bicarbonate, mmol/L 18.3 (5.4) 16.4 (5.9) 0.37
Total calcium (mmol/L) 2.31 (0.24) 2.28 (0.23) 0.51
Ionized calcium (mmol/L) 1.13 (0.12) 1.12 (0.11) 0.54
Severity score data
Sepsis 32 (60) 31 (63) 0.76
Oliguria 34 (69) 35 (71) 0.83
Inotropic support 31 (60) 30 (61) 0.87
Mechanical ventilation 32 (62) 28 (57) 0.65
APACHE II score 28 (9) 29 (9) 0.58
SAPS score 63 (18) 65 (18) 0.61
Data are expressed as mean (SD). Categorical data are expressed as number (%). BUN, blood urea nitrogen; INR, internal normalized ratio; PTT, partial
thromboplastin time; APACHE, acute physiology and chronic health evaluation; SAPS, simplified acute physiology score.
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ionized hypocalcemia responded well to increased cal-
cium supplementation. Five patients were switched
from heparin to citrate: two patients with major bleed-
ing, and three because of recurrent filter clotting.
Metabolic disorders and episodes of bleeding are listed
in Table 2.Mortality
In the intention-to-treat analysis, 28- to 90-day mortality
rates were 20 to 26% and 26 to 27% in the citrate and
heparin groups, respectively (P = 0.37). In the perprotocol analysis, 90-day mortality rates were 27%
and 30% in the citrate and heparin groups, respect-
ively (P = 0.33). The 90-day mortality rate in the 246
critically ill patients treated by CRRT during the
study period was 38%.Length of CRRT and stay
RRT duration was slightly longer for patients in the hep-
arin group, although the difference did not reach statistical
significance (Table 2). Median duration of ICU stay was
similar in both groups. Median duration of hospitalization
















Figure 2 Kaplan-Meier analysis of the filter lifespan.
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Nine patients remain RRT-dependent, five in the heparin
group, and four in the citrate group at 90-day follow up.
Subgroup of patients with liver failure
Twelve patients with liver failure, defined as previously
known to have cirrhotic disease or acute elevation of
amino transferases associated with prolonged clotting
time and encephalopathy, in whom factor V was still >20%
at screening, have been enrolled in the study. Among these
patients, six were randomized into the citrate group, of
whom four survived >90 days. RCA was well-tolerated and
implemented without any subsequent metabolic disorders
in these patients.
Discussion
Since the initial publication by Mehta et al., RCA has
slowly gained support among nephrologists and intensi-
vists treating ICU patients with AKI requiring CRRT
[15]. However, its widespread use is hampered by fears
of severe metabolic side-effects, such as citrate accumu-
lation leading to hypocalcemia and acid-base disorders
[7,16]. Our results show that citrate-based regional
anticoagulation is safe, and that metabolic complications
are rare when a standardized protocol is used to adapt
dialysate flow and calcium substitution in order to main-
tain blood pH and ionized calcium levels within the nor-
mal range.
We used a commercially available balanced predilution
replacement solution, with an administered volume
coupled to blood flow in order to minimize caregiver-
induced manipulation errors. Filter lifespan and thus,
effective daily RRT dose, were significantly increasedwith this RCA protocol. RCA dramatically decreases
the filter clotting, which is a frequent complication of
CRRT, especially in patients with acute critical illness
such as sepsis, where thrombogenicity is increased
[17]. An increased filter lifespan means less treatment
interruption and more effective dialysis time. One of
the most frequent problems encountered in these
patients treated by CRRT is indeed circuit downtime,
implying that delivered RRT dose is often lower than
prescribed [18]. We found that filter clotting occurred
only in 6% of the patients within the RCA group versus
37% of the patients within the heparin group. This fa-
vorable effect was shown in many, but not all, prior
publications which are encompassed in two recent
meta-analyses, leading to the sound conclusion that
citrate may be more effective that heparin in terms of
filter lifespan [5,19-22].
A few studies have evaluated the safety and efficacy of
custom-made citrate solutions. In a recent multicenter
randomized study, a custom-made calcium-free triso-
dium citrate replacement fluid (13.3 mmol citrate/L) was
compared with bicarbonate- and lactate-based replace-
ment solutions in ICU patients [8]. No difference was
found for 28- and 90-day mortality when using citrate as
compared to bicarbonate- and lactate-based replacement
solutions. Six percent of the patients randomized to
RCA had citrate accumulation, which led to RCA inter-
ruption, as compared to one third of heparin interrup-
tion within the other group. Citrate was found to be
superior in terms of safety and cost-effectiveness. The
lower rate of citrate accumulation in our patients is
probably due to the fact that our patients represented a
different population, as patients with severe liver failure
were excluded.
In an uncontrolled retrospective study with a citrate-
based commercially available solution, 16 cases of citrate
accumulation and 4 cases of CVVH termination due to
citrate accumulation were reported [23]. This unexpect-
edly high rate of complication may have been related to
the very high CVVH dose (45 ml/kg/h) that was used in
this study. Moreover, the necessity of an exogenous infu-
sion of sodium bicarbonate may have increased the com-
plexity of the procedure.
Another prospective observational uncontrolled trial
has recently been conducted to assess the safety of a
custom-made, not yet commercially available, citrate
solution [24] in patients prone to bleeding. CVVH with
RCA was found to be safe in these patients, and citrate
had to be withdrawn in only 11% of the patients, espe-
cially in patients with higher transaminases. This rate
is higher than in our study, probably related to the
number of patients with moderate to severe liver dis-
ease in this study and to the lower citrate flow that we
used.
Table 2 Intervention data
Variables Citrate Heparin p
(n = 54) (n = 49)
Delivered RRT dose, ml/kg/h 29 (3) 27 (5) 0.005
Effective delivered RRT dose*, ml/kg/h 28 (5) 26 (4) 0.15
Filter lifespan, h 49 (29) 28 (23) 0.004
Mean heparin, IU/ml dose 6,757 (5,455) 10,567 (7,760) 0.005
Laboratory follow-up data
Total calcium, mmol/L, day 1 2.34 (0.20) 2.31 (0.19) 0.56
Ionized calcium, mmol/L, day 1 1.05 (0.10) 1. 12 (0.09) 0.04
pH, day 1 7.32 (0.10) 7.31 (0.11) 0.62
Bicarbonate, mmol/L, day 1 18 (4.6) 19 (7.2) 0.96
Na, mmol/L, day 1 136 (15) 138 (7) 0.42
Chloride, mmol/L, day 1 104 (15) 108 (7) 0.15
Potassium, mmol/L, day 1 6 (14) 5.3 (5.6) 0.61
Lactate, mmol/L, day 1 1.3 (0.9 to 2.9) 1.3 (0.8 to 1.8) 0.67
Total calcium, mmol/L, day 3 2.52 (0.19) 2.41 (0.22) 0.02
Ionized calcium, mmol/L, day 3 1.14 (0.10) 1.20 (0.11) 0.01
pH, day 3 7.40 (0,06) 7.41 (0.06) 0. 39
Bicarbonate, mmol/L, day 3 23.71 (1.81) 25.17 (4.31) 0.43
Na, mmol/L, day 3 138 (3.37) 138 (4) 0.71
Chloride, mmol/L, day 3 104 (3.4) 107 (4) 0.00
Potassium, mmol/L, day 3 4 (0.52) 4.3 (0.6) 0.03
Lactate, mmol/L, day 3 1.4 (0.9 to 2.2) 1.1 (0.9 to 1.4) 0.50
Side effects 32 27 0.17
Bleeding 0 4 (8)
HIT 1 (2) 2 (4)
Filter clotting 3 (6) 18 (37)
Metabolic disorders: 14 3
Metabolic alcalosis 3 0
Respiratory alkalosis 0 1
Metabolic acidosis 3 1
Severe hypocalcemia 6 1
Ca total/calcium ion ratio >2.5 1 0
CRRT, days 3 (2 to 6) 3 (2 to 5) 0.30
ICU, days 7 (4 to 15) 7 (4 to 12) 0.79
Hospital, days 22 (6 to 35) 16 (9 to 30) 0.45
Survival at 28 days 43 (80) 36 (74) 0.46
Survival at 90 days 40 (74) 35 (73) 0.90
Data are expressed as mean (SD) or median (IQR) according to the distribution, and categorical data are expressed as number (%). *Including elective filter
downtime. RRT, renal replacement therapy; CRRT, continuous renal replacement therapy.
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more metabolic side effects. The clinical impact was
minor as only two patients had to be switched to hep-
arin on account of severe hypocalcemia. In comparison,
five patients in the heparin group had to be changed to
RCA on account of clinically significant bleeding orrecurrent filter clotting. In terms of safety issues, RCA
seems therefore to have a favorable profile.
In the subgroup of 12 patients with liver failure but
with factor V >20%, RCA treatment was tolerated as well
as heparin. Due to the small number of patients, it is dif-
ficult to draw any conclusion about the safety of RCA in
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patients with the worst liver function (defined as a factor
V <20%). Results from a prospective observational study
investigating citrate accumulation in patients with
decompensated liver cirrhosis or acute liver failure were
recently published. Twenty-eight patients received citrate-
based CCVHDF and even though these patients had a
higher total calcium/ionized calcium ratio, which reflects
citrate accumulation, major disturbances of acid-base or
electrolyte status were not found [25].
Although this was not our primary objective, we were
unable to show a significant reduction in mortality with
RCA use, as observed in the largest published RCA trial
(7). This positive effect of citrate anticoagulation on
survival was noted especially in patients with sepsis and
in patients with higher severity scores. In this trial, the
90-day mortality was 63% in the nadroparin group ver-
sus 48% in the RCA group. This survival advantage how-
ever, was not observed in another recently published
RCT, where 174 patients requiring RRT were random-
ized to RCA versus standard heparin [8]. Different expla-
nations could account for the discrepancies on mortality
between our results and those of the Dutch trial [7].
First, the overall mortality (20 and 23.9%) is remarkably
low in our trial and clearly lower than what has been de-
scribed so far in similar populations. Lower mortality
seems to be common in recently published RCTs in the
ICU setting, most probably reflecting improvement in
the standard of care. Second, our sample size does not
allow us to detect a significant change in mortality.
Mean age and percentage of surgical patients and those
on mechanical ventilation were also higher in the Dutch
trial than in our trial, which could also explain the high-
est mortality rate. Finally, low-molecular-weight heparin
was used in that trial compared with the unfractionated
heparin in our study.
Our study has several limitations. First, it is relatively
small, therefore underpowered to detect beneficial effects
other than filter lifespan and more efficient delivery of the
RRT dose. It is monocentric and cannot be generalized to
other ICUs, as our patient management involved two
medical teams of nephrologists and intensivists working
closely together. Second, a direct measurement of the dia-
lysis dose with urea clearance could not be measured for
practical reasons, and we used the delivered RRT dose cal-
culated on treatment duration as a proxy for dialysis
efficiency.
Conclusion
Notwithstanding, our results show that metabolic compli-
cations of RCA can be avoided with the help of a strict
protocol and the use of a commercially available predilu-
tion citrate fluid, with a safety profile that looks promising.
We also confirm that hemorrhagic complications can beavoided with RCA. Although RCA use did not translate
into an improvement in 90-day survival in our trial (which
was underpowered for this endpoint), there is a clear
advantage of RCA over heparin-based anticoagulation in
terms of filter lifespan and effective daily delivered RRT
dose.
Key messages
 In ICU patients with AKI treated with continuous
RRT, regional citrate anticoagulation is superior to
heparin in terms of filter life span and delivered RRT
dose
 Metabolic complications of RCA can be avoided
with the help of a strict protocol
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